TheraRadar
Data updated: Jun 28, 2026

TRIMETHOPRIM · Teva

Generic · see TRIMPEX 200 Cytochrome P450 2C9 Inhibitors
Infectious Disease Approved 1980-05-30

To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets, USP and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.

7
Indications
--
Phase 3 Trials
46
Years on Market

Details

Status
Discontinued
First Approved
1980-05-30
Routes
ORAL
Dosage Forms
TABLET

TRIMETHOPRIM Approval History

1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
86 FDA actions from 1982 to 2025
Mar 2025 SUPPL
Label · Labeling
Oct 2022 ORIGINAL
Update
Aug 2016 SUPPL
Mfg · Manufacturing (CMC)

What TRIMETHOPRIM Treats

2 indications

TRIMETHOPRIM is approved for 2 conditions since its original approval in 1982. These indications span multiple therapeutic areas including oncology, immunology, and more.

Source: FDA Label

TRIMETHOPRIM Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to TRIMETHOPRIM

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

BACTRIM
SULFAMETHOXAZOLE
2 shared
Sun Pharma
BACTRIM DS
SULFAMETHOXAZOLE
2 shared
Sun Pharma
CEFPODOXIME PROXETIL
CEFPODOXIME PROXETIL
2 shared
Aurobindo Pharma

Teva's other novel FDA approvals

Other CDER-designated drugs from the same sponsor (2016–2025).

📋

Clinical Trial Registry

4 trials
Trial Sponsor ID Phase Status Title
NCT06709196 REINFORCE 2024-514312-27-00 2024-514312-27-00 Ph 4 recruiting Clinical Trial Testing Whether Targeted Antibiotic Prophylaxis Can Reduce Infections After Cystectomy Compared to Empiric Prophylaxis
NCT03746106 results posted 13060 5R01DK108722-02 Ph 4 completed The Effect of SLC19A3 Inhibition on the Pharmacokinetics of Thiamine
NCT03077711 results posted EH16-216 Ph 4 completed Methenamine Hippurate Versus Trimethoprim in the Prevention of Recurrent UTIs
NCT02188472 PENTRIOX PEN1011 Ph 1 completed Pentriox - Induction of Oxidative Stress
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

TRIMETHOPRIM FDA Label Details

Indications & Usage

FDA Label (PDF)

To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets, USP and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Uri...

Looking for the branded version?

TRIMPEX 200

Full clinical data, patents, trials, and competitive landscape for trimethoprim.

See TRIMPEX 200

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.